Table A2.
Recurrence and HRs for BRAF V600E Mutation–Positive Versus -Negative Patients in Various Tumor Size Groups of PTC (all types)
| Tumor Size Category (cm) | Recurrence |
HR | 95% CI | P | |||
|---|---|---|---|---|---|---|---|
|
BRAF Mutation Positive |
BRAF Mutation Negative |
||||||
| No. | % | No. | % | ||||
| 1.0 to 2.0 | 68 of 472 | 14.4 | 40 of 451 | 8.9 | 1.69 | 1.14 to 2.50 | .009 |
| 2.0 to 3.0 | 60 of 292 | 20.6 | 37 of 263 | 14.1 | 1.66 | 1.09 to 2.50 | .02 |
| 3.0 to 4.0 | 49 of 164 | 29.9 | 34 of 171 | 19.9 | 1.41 | 0.90 to 2.19 | .13 |
| ≥ 4.0 | 55 of 129 | 42.6 | 29 of 146 | 19.9 | 1.88 | 1.20 to 2.95 | .006 |
Abbreviations: HR, hazard ratio; PTC, papillary thyroid cancer.